Biological activity exerted by an amino-steroid-anthracenone derivative (ASA; 0.001-100 nM) against ischemia-reperfusion injury (translated as infarct area). The experimental data showed that ASA decreased infarct size (expressed as a percentage of the area at risk) in a dose-dependent manner compared with the vehicle-treated hearts (control). Each bar represents the mean ± S.E. of 9 experiments.
Back to Article